Kana Watanabe

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study

Kaname Nosaki, Miyako Satouchi, Takayasu Kurata et al. · Lung Cancer · 2016 · 135 citations · Full text

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

Koutaroh Okada, Mitsugu Araki, Takuya Sakashita et al. · EBioMedicine · 2019 · 125 citations · Full text

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Hayato Mizuta, Koutaroh Okada, Mitsugu Araki et al. · Nature Communications · 2021 · 99 citations · Full text

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated <i>EGFR</i>

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura et al. · Journal of Clinical Oncology · 2022 · 89 citations · Full text